Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Rezolute, Inc.
Rezolute, Inc. News
Jul 22, 2025 - globenewswire.com
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Jul 9, 2025 - globenewswire.com
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
Rezolute, Inc. Quantitative Score
About Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Rezolute, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Rezolute, Inc. Financials
Table Compare
Compare RZLT metrics with: | |||
|---|---|---|---|
Earnings & Growth | RZLT | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | RZLT | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | RZLT | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | RZLT | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Rezolute, Inc. Income
Rezolute, Inc. Balance Sheet
Rezolute, Inc. Cash Flow
Rezolute, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Rezolute, Inc. Executives
| Name | Role |
|---|---|
| Mr. Nevan Charles Elam J.D. | Founder, Chief Executive Officer, Principal Financial Officer & Acting Chairman of the Board |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer |
| Mr. Daron G. Evans M.B.A., M.S. | Chief Financial Officer |
| Dr. Raj Agrawal M.D. | Vice President & Head of Ophthalmological Clinical Development |
| Mr. Michael R. Deperro | Senior Vice President & Head of Corporate Development |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Nevan Charles Elam J.D. | Founder, Chief Executive Officer, Principal Financial Officer & Acting Chairman of the Board | Male | 1967 | 915.67K |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer | 1975 | 712.04K | |
| Mr. Daron G. Evans M.B.A., M.S. | Chief Financial Officer | Male | 1974 | 183.04K |
| Dr. Raj Agrawal M.D. | Vice President & Head of Ophthalmological Clinical Development | -- | ||
| Mr. Michael R. Deperro | Senior Vice President & Head of Corporate Development | Male | -- |
Rezolute, Inc. Insider Trades
| Date | 25 Jun |
| Name | ROBERTS BRIAN KENNETH |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 2500 |
| Date | 24 Jun |
| Name | Evans Daron |
| Role | CFO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 5000 |
| Date | 13 Jun |
| Name | Kim Young-Jin |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 1230769 |
| Date | 13 Jun |
| Name | KREHER NERISSA |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 3076 |
| Date | 10 Jun |
| Name | KREHER NERISSA |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 9000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 25 Jun | ROBERTS BRIAN KENNETH | Chief Medical Officer | Acquired | P-Purchase | 2500 |
| 24 Jun | Evans Daron | CFO | Acquired | P-Purchase | 5000 |
| 13 Jun | Kim Young-Jin | Director | Acquired | P-Purchase | 1230769 |
| 13 Jun | KREHER NERISSA | Director | Acquired | P-Purchase | 3076 |
| 10 Jun | KREHER NERISSA | Director | Acquired | A-Award | 9000 |